Category:

InPlay Oil Corp. Announces Second Quarter 2025 Financial and Operating Results and Provides Operations Update

Posted on by aweinsoff@channelchek.com
InPlay Oil Logo (CNW Group/InPlay Oil Corp.)

Research News and Market Data on IPOOF

Aug 14, 2025, 07:30 ET

CALGARY, AB, Aug. 13, 2025 /CNW/ – InPlay Oil Corp. (TSX: IPO) (OTCQX: IPOOF) (“InPlay” or the “Company“) announces its financial and operating results for the three and six months ended June 30, 2025 which is our first quarter following the April 7, 2025 closing date of the strategic acquisition of Cardium focused light oil assets in the Pembina area of Alberta (the “Acquisition“). InPlay’s condensed unaudited interim financial statements and notes, as well as its Management’s Discussion and Analysis (“MD&A”) for the three and six months ended June 30, 2025 will be available at “www.sedarplus.ca” and on our website at “www.inplayoil.com“. An updated corporate presentation is available on our website.

We are excited about InPlay’s future following the highly accretive acquisition completed in the second quarter. This transformative transaction has significantly enhanced the Company’s scale, market capitalization, and long-term sustainability. With a longer reserve life and an expanded inventory of high quality drilling locations, the combined Company is well positioned to generate strong free adjusted funds flow (“FAFF”)(3) for many years to come.

InPlay is off to a very strong start with second quarter production exceeding expectations by approximately 1,000 boe/d. This outperformance was driven by base production performing above expectations and seven (7.0 net) wells brought onstream in March significantly outperforming our type curves by ~135% on average based on the first 120 days of initial production (“IP”). Notably, three wells brought onstream in March ranked among the top ten Cardium producers in April with two of them holding the number one and two spots in April and May, and ranking second and third in June. These wells achieved payout in under 90 days in a US$60 WTI pricing environment. As a result of this outperformance, current production based on field estimates remains at 19,400 boe/d even though no new wells have been brought on since March. We now expect 2025 average production to be at the upper end of our guidance range. In addition, strong capital efficiencies are expected to result in capital spending landing in the lower half of our previously announced capital budget of $53 – $60 million. The Company continues to prioritize free cash flow generation to be used for debt reduction and the continued return of capital to shareholders through our monthly dividend.

Another exciting development is the recent announcement that Delek Group Ltd. (“Delek”) has become a 32.7% strategically aligned shareholder of InPlay. Delek brings a proven track record of value creation in the energy sector. They hold a 45% working interest in the largest natural gas field in the Mediterranean, with an estimated 23 TCF of recoverable natural gas. Additionally, Delek has been instrumental in the growth of Ithaca Energy plc, where they hold a 52% equity stake and have overseen production growth from 30,000 boe/d to over 120,000 boe/d since 2019.

For the remainder of 2025, InPlay plans to drill 5.0 – 5.5 net Cardium wells in Pembina. InPlay’s second half drilling campaign recently commenced in August, with the spudding of a three well pad which are in close proximity to the Company’s top producing Cardium wells and are expected to be on production near the beginning of October. The application of InPlay’s drilling and completion techniques to the acquired assets is expected to drive continued strong performance from new wells with additional capital directed to facility upgrades, optimization and required infrastructure projects.

InPlay will continue to be disciplined and timely in capital spending in the current commodity price environment, maintaining a focus on strong FAFF, debt reduction, per share growth and continuation of our return to shareholder strategy. To further enhance stability and mitigate risk, the Company has secured commodity hedges extending through 2025 and into 2026. InPlay has hedged over 70% of natural gas production and approximately 60% of light crude oil production for the second half of 2025.

Second Quarter 2025 Highlights

  • Successfully closed the strategic acquisition of Cardium focused light oil assets at highly accretive metrics, enhancing FAFF by 65% on a per share basis, expanding our drilling inventory to over 400 locations, lowering our corporate base decline rate to 24% and strengthening dividend sustainability (2025 forecasted FAFF equal to 2.5 times base dividend).
  • Achieved average quarterly production of 20,401 boe/d(1) (62% light crude oil and NGLs), a 125% increase from Q1 2025, including a 13% increase to light crude oil and liquids weighting to 62% from 55% and a 35% increase in light oil weighting to 51% from 38% in the first quarter of 2025 with oil being the main driver behind our netbacks.
  • Generated strong quarterly Adjusted Funds Flow (“AFF”)(2) of $40.1 million ($1.49 per basic share(3)).
  • Achieved significant FAFF of $35.5 million ($1.32 per basic share(3)) allowing the Company to reduce net debt by approximately $26 million, more than originally forecasted, resulting in a quarterly annualized net debt to earnings before interest, taxes and depreciation (“EBITDA”)(3) ratio of 1.2 times.
  • Realized operating income of $50.5 million(3), an increase of 140% compared to Q1 2025 leading to a strong operating income profit margin(3) of 55%, up from 54% in Q1 2025.
  • Improved field operating netbacks(3) to $27.20/boe, a 6% increase compared to Q1 2025 despite an 11% decrease to WTI pricing (13% decrease to realized crude oil pricing) and a 22% decrease in AECO natural gas pricing compared to Q1 2025.
  • Returned $7.9 million to shareholders via monthly dividends, representing a 10% yield relative to the current share price. Since November 2022, InPlay has distributed $52 million in dividends (including dividends declared to date in the third quarter).

Second Quarter 2025 Financial & Operations Overview:

InPlay’s second quarter results exceeded expectations and marked the first reporting period incorporating the recently acquired assets, with pro forma operations effective April 8, 2025. Due to the outstanding efforts of our team and InPlay’s strong knowledge and focus in the area, the acquired assets were seamlessly integrated with no disruption to the Company’s ongoing operations.

Quarterly production averaged 20,401 boe/d(1) (62% light crude oil and NGLs) which was approximately 1,000 boe/d above internal forecasts. Base production exceeded expectations, and the seven (7.0 net) wells drilled on the combined assets in the first quarter significantly outperformed internal forecasts by approximately 135% (based on IP 120) as highlighted in the table below.

02-25 Pad (per well average)14-33 Pad (per well average)08-01 Pad (per well average)
boe/dOil and NGLs %boe/dOil and NGLs %boe/dOil and NGLs %
IP 3088788 %68075 %26589 %
IP 6093787 %49366 %29087 %
IP 9092285 %56963 %28886 %
IP 12089285 %43060 %28583 %
IP 150 N/AN/A48758 %27582 %
Current79182 %29944 %21777 %
>300% above type curve>75% above type curve>25% above type curve

InPlay generated AFF of $40.1 million ($1.49 per basic share) a 138% increase from the first quarter of 2025. Limited capital spending in the second quarter of $4.6 million, resulted in $35.5 million of FAFF ($1.32 per basic share), highlighting the strong FAFF generation of the combined Company. These strong results were achieved despite an 11% decrease to WTI pricing (13% decrease to realized crude oil pricing) and a 22% decrease in AECO natural gas pricing compared to Q1 2025. The Company paid $7.9 million ($12.0 million in the first half of 2025) in dividends during the quarter.

During the quarter InPlay generated a net loss of $3.2 million. After excluding one-time transaction costs and the impact of unrealized mark-to-market hedging gains/losses, InPlay generated adjusted net income(3) of $2.0 million ($0.08 per basic share) in the quarter.

Strong results had net debt levels at the end of the quarter at $223 million, $5 million lower than originally anticipated. The quarterly annualized net debt to EBITDA ratio for the second quarter of 1.2x is evidence that our post-Acquisition accelerated debt reduction goals are well on track.

Operating synergies and stronger production allowed InPlay to maintain operating costs per boe in the second quarter in line with pre-acquisition levels and synergies have started to show a reduction in G&A cost per boe.

Financial and Operating Results:

(CDN) ($000’s)Three months ended
June 30		Six months ended
June 30
2025202420252024
Financial
Oil and natural gas sales91.641.5130.679.5
Adjusted funds flow(2)40.120.156.936.7
    Per share – basic(3)(5)1.491.342.712.44
    Per share – diluted(3) (5)1.491.302.712.36
    Per boe(3)21.5925.5721.2723.34
Comprehensive income (loss)(3.2)5.4(6.1)7.1
Per share – basic(5)(0.12)0.36(0.29)0.47
Per share – diluted(5)(0.12)0.35(0.29)0.46
Dividends7.94.112.08.2
Per share0.090.090.090.09
Capital expenditures – PP&E and E&E4.66.218.531.7
Property acquisitions (dispositions)293.3–293.6(0.0)
Net debt(2)(223.2)(50.8)(223.2)(50.8)
Shares outstanding(5)27.815.027.815.0
Basic weighted-average shares(5)26.915.021.015.0
Diluted weighted-average shares(5)26.915.521.015.5
Operational
Daily production volumes
Light and medium crude oil (bbls/d)10,3283,6716,8983,561
Natural gas liquids (boe/d)2,4011,4381,9891,462
Conventional natural gas (Mcf/d)46,02921,29135,30021,645
Total (boe/d)20,4018,65714,7708,631
Realized prices(3)
Light and medium crude oil & NGLs ($/bbls)75.1383.2472.5078.07
Conventional natural gas ($/Mcf)1.831.432.002.05
Total ($/boe)49.3652.6348.8450.58
Operating netbacks ($/boe)(4)
Oil and natural gas sales49.3652.6348.8450.58
Royalties(6.35)(6.43)(6.20)(6.10)
Transportation expense(0.71)(0.98)(0.84)(1.04)
Operating costs(15.10)(14.81)(15.06)(15.09)
    Operating netback(4)27.2030.4126.7428.35
Realized gain (loss) on derivative contracts(0.20)0.25(0.12)0.27
    Operating netback (including realized derivative contracts) (4)27.0030.6626.6228.62

On behalf of the entire InPlay team and our Board of Directors, we thank our shareholders for their ongoing support as we execute our strategy of disciplined growth, reliable returns, and long-term value creation. We would like to send a special thanks to our employees for their significant effort in enabling a smooth integration of the new assets. We are very optimistic about building on the momentum from our strategic Acquisition that has transformed the future of the Company.

Notes:
1.See “Production Breakdown by Product Type” at the end of this press release.
2.Capital management measure. See “Non-GAAP and Other Financial Measures” contained within this press release.
3.Non-GAAP financial measure or ratio that does not have a standardized meaning under International Financial Reporting Standards (IFRS) and GAAP and therefore may not be comparable with the calculations of similar measures for other companies. Please refer to “Non-GAAP and Other Financial Measures” contained within this press release and in our most recently filed MD&A.
4.Supplementary measure. See “Non-GAAP and Other Financial Measures” contained within this press release.
5.Common share and per common share amounts have been updated to reflect the six for one (6:1) common share consolidation effective April 14, 2025.

For further information please contact:

Doug Bartole
President and Chief Executive Officer
InPlay Oil Corp.
Telephone: (587) 955-0632		Darren Dittmer
Chief Financial Officer
InPlay Oil Corp.
Telephone: (587) 955-0634

View full release here.

Release – NIH Contract Expands DLH’s Position as a Digital Transformation and Cybersecurity Leader

Posted on by aweinsoff@channelchek.com

Research News and Market Data on DLHC

August 14, 2025

PDF Version

Company to Continue Providing Information Technology Services for National Institutes of Health

ATLANTA, Aug. 14, 2025 (GLOBE NEWSWIRE) — DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of digital transformation and cyber security, science research and development, and systems engineering and integration, today announced that it has been awarded a task order valued at up to $46.9 million to continue providing information technology services including enterprise IT systems management, cyber security, software development, cloud computing, and more to the National Institutes of Health’s Office of Information Technology (“OIT”). OIT plays a central role in providing and supporting the information technology resources necessary to execute NIH’s critical health missions.

“With our unique position at the intersection of scientific research and advanced technology, DLH remains a natural partner for innovation alongside the National Institutes of Health,” said Zach Parker, DLH President and CEO. “DLH engineers, application developers, and IT will continue to bring their industry-leading information technology, systems integration, and customer support expertise to provide crucial support for this customer while also asked to conduct technology assessments and impact strategic modernization plans.”

This $46.9 million task order includes a base period and multiple options aggregating to a three-year period of performance. Through this award, DLH will leverage a comprehensive suite of digital transformation and cyber security solutions to support approximately 7,000 end-customers. As part of this new effort, DLH will design and implement a cloud migration strategy built on partnerships with leading commercial CSP vendors including Azure, AWS, and Google.

“DLH will continue to test, validate, refine, and incubate bold new ideas and innovation on behalf of the vital work our customers carry out,” said Diane Yarnell, President, Health IT. “Our experts deliver full project management life-cycle solutions to modernize IT, improve the customer experience and business processes, optimize systems, train personnel, and integrate emerging technologies such as artificial intelligence.”

About DLH

DLH (NASDAQ: DLHC) enhances technology, public health, and cyber security readiness missions through science, technology, cyber, and engineering solutions and services. Our experts solve some of the most complex and critical missions faced by customers today, leveraging digital transformation, artificial intelligence, advanced analytics, cloud-based applications, telehealth systems, and more. With over 2,400 employees dedicated to the idea that “Your Mission is Our Passion,” DLH brings a unique combination of technology, innovation, and world-class expertise, to improve lives across the globe. For more information, visit www.DLHcorp.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or DLH`s future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that the Company or its management “believes”, “expects”, “anticipates”, “plans”, “intends” and similar expressions) should be considered forward looking statements that involve risks and uncertainties which could cause actual events or DLH’s actual results to differ materially from those indicated by the forward-looking statements. Forward-looking statements in this release include, among others, statements regarding estimates of future revenues, operating income, earnings and cash flow. These statements reflect our belief and assumptions as to future events that may not prove to be accurate. Our actual results may differ materially from such forward-looking statements made in this release due to a variety of factors, including: the risk that we will not realize the anticipated benefits of acquisitions (including anticipated future financial performance and results); the diversion of management’s attention from normal daily operations of the business and the challenges of managing larger and more widespread operations; the inability to retain employees and customers; contract awards in connection with re-competes for present business and/or competition for new business; our ability to manage our debt obligations; compliance with bank financial and other covenants; changes in client budgetary priorities; government contract procurement (such as bid and award protests, small business set asides, loss of work due to organizational conflicts of interest, etc.) and termination risks; the impact of inflation and higher interest rates; and other risks described in our SEC filings. For a discussion of such risks and uncertainties which could cause actual results to differ from those contained in the forward-looking statements, see “Risk Factors” in the Company’s periodic reports filed with the SEC, including our Annual Report on Form 10-K for the fiscal year ended September 30, 2024 as well as subsequent reports filed thereafter. The forward-looking statements contained herein are not historical facts, but rather are based on current expectations, estimates, assumptions and projections about our industry and business.

Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company does not assume any responsibility for updating forward-looking statements, except as may be required by law.

CONTACTS:
INVESTOR RELATIONS
Contact: Chris Witty
Phone: 646-438-9385
Email: cwitty@darrowir.com

Release – Hemisphere Energy Announces 2025 Second Quarter Results, Declares Quarterly Dividend, and Provides Operations Update

Posted on by aweinsoff@channelchek.com

Research News and Market Data on HMENF

August 14, 2025 8:00 AM EDT | Source: Hemisphere Energy Corporation

Vancouver, British Columbia–(Newsfile Corp. – August 14, 2025) – Hemisphere Energy Corporation (TSXV: HME) (OTCQX: HMENF) (“Hemisphere” or the “Company”) provides its financial and operating results for the second quarter ended June 30, 2025, declares a quarterly dividend payment to shareholders, and provides operations update.

Q2 2025 Highlights

  • Attained quarterly production of 3,826 boe/d (99% heavy oil).
  • Generated $24.4 million, or $70.06/boe, in revenue.
  • Achieved total operating and transportation costs of $14.18/boe.
  • Delivered an operating field netback1 of $14.9 million, or $42.77/boe.
  • Realized quarterly adjusted funds flow from operations (“AFF”)1 of $10.3 million, or $29.47/boe.
  • Executed a $2.2 million capital expenditure1 program, including preparatory spending for Hemisphere’s upcoming drilling program.
  • Generated free funds flow1 of $8.1 million, or $0.07/share.
  • Distributed $2.4 million, or $0.025/share, in base dividends to shareholders during the quarter.
  • Distributed $2.9 million, or $0.03/share, in special dividends to shareholders during the quarter.
  • Purchased and cancelled 1.3 million shares for $2.3 million under the Company’s Normal Course Issuer Bid (“NCIB”).
  • Renewed the Company’s $35 million two-year extendible credit facility.
  • Exited the first quarter with positive working capital1 of $13.9 million.
(1) Operating field netback, adjusted funds flow from operations (AFF), free funds flow, capital expenditure, and working capital are non-IFRS measures, or when expressed on a per share or boe basis, non-IFRS ratio, that do not have any standardized meaning under IFRS and therefore may not be comparable to similar measures presented by other entities. Non-IFRS financial measures and ratios are not standardized financial measures under IFRS and may not be comparable to similar financial measures disclosed by other issuers. Refer to the section “Non-IFRS and Other Specified Financial Measures”.

Selected financial and operational highlights should be read in conjunction with Hemisphere’s unaudited condensed interim consolidated financial statements and related notes, and the Management’s Discussion and Analysis for the three months ended June 30, 2025 which are available on SEDAR+ at www.sedarplus.ca and on Hemisphere’s website at www.hemisphereenergy.ca. All amounts are expressed in Canadian dollars unless otherwise noted.

Quarterly Dividend

Hemisphere is pleased to announce that its Board of Directors has approved a quarterly base cash dividend of $0.025 per common share in accordance with the Company’s dividend policy. The dividend will be paid on September 12, 2025 to shareholders of record as of the close of business on August 29, 2025. The dividend is designated as an eligible dividend for income tax purposes.

Operations Update

With significant volatility in the economy and oil markets earlier this year, Hemisphere elected to defer the majority of its capital spending into the latter third of the year. With relatively flat base production, the Company has focused on balance sheet strength and shareholder returns through its share buyback program, base quarterly dividends, and the announcements of two special dividends year-to-date.

The Company’s drilling program is now scheduled to commence late in the third quarter. It will include several development wells in Atlee Buffalo in addition to at least one new well in Marsden, which will test a second oil-bearing zone on Hemisphere’s lands adjacent to its oil treating facilities and active polymer pilot project.

Management will continue to closely monitor oil market volatility and adjust capital spending accordingly. With almost $14 million in working capital, an undrawn credit line, and stable cash flow from its production base, Hemisphere is in a unique position to act on potential acquisition opportunities and continued shareholder returns in addition to executing its drilling program.

EnerCom Denver Conference

Ms. Ashley Ramsden-Wood, Chief Development Officer of Hemisphere, will be presenting at the EnerCom Denver Conference on Tuesday, August 19 at 2:45 pm Mountain Daylight Time (1:45 pm Pacific Daylight Time). The presentation will be livestreamed on EnerCom’s website at www.enercomdenver.com/webcast (Confluence C) and archived on Hemisphere’s website at www.hemisphereenergy.ca.

About Hemisphere Energy Corporation

Hemisphere is a dividend-paying Canadian oil company focused on maximizing value-per-share growth with the sustainable development of its high netback, ultra-low decline conventional heavy oil assets through polymer flood enhanced oil recovery methods. Hemisphere trades on the TSX Venture Exchange as a Tier 1 issuer under the symbol “HME” and on the OTCQX Venture Marketplace under the symbol “HMENF”.

For further information, please visit the Company’s website at www.hemisphereenergy.ca to view its corporate presentation or contact:

Don Simmons, President & Chief Executive Officer
Telephone: (604) 685-9255
Email: info@hemisphereenergy.ca

Website: www.hemisphereenergy.ca

Forward-looking Statements

Certain statements included in this news release constitute forward-looking statements or forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as “anticipate”, “continue”, “estimate”, “expect”, “forecast”, “may”, “will”, “project”, “could”, “plan”, “intend”, “should”, “believe”, “outlook”, “potential”, “target” and similar words suggesting future events or future performance. In particular, but without limiting the generality of the foregoing, this news release includes forward-looking statements including that Hemisphere’s drilling program is now scheduled to commence late in the third quarter and will include several development wells in Atlee Buffalo in addition to at least one new well in Marsden, which will test a second oil-bearing zone on Hemisphere’s lands; that Hemisphere may adjust capital spending depending on oil market volatility; that Hemisphere is in a unique position to act on potential acquisition opportunities and continued shareholder returns; and that a dividend will be paid September 12, 2025 to shareholders of record as of the close of business on August 29, 2025.

Forward‐looking statements are based on a number of material factors, expectations or assumptions of Hemisphere which have been used to develop such statements and information but which may prove to be incorrect. Although Hemisphere believes that the expectations reflected in such forward‐looking statements or information are reasonable, undue reliance should not be placed on forward‐looking statements because Hemisphere can give no assurance that such expectations will prove to be correct. In addition to other factors and assumptions which may be identified herein, assumptions have been made regarding, among other things: the current and go-forward oil price environment; that Hemisphere will continue to conduct its operations in a manner consistent with past operations; that results from drilling and development activities are consistent with past operations; the quality of the reservoirs in which Hemisphere operates and continued performance from existing wells; the continued and timely development of infrastructure in areas of new production; the accuracy of the estimates of Hemisphere’s reserve volumes; certain commodity price and other cost assumptions; continued availability of debt and equity financing and cash flow to fund Hemisphere’s current and future plans and expenditures; the impact of increasing competition; the general stability of the economic and political environment in which Hemisphere operates; the general continuance of current industry conditions; the timely receipt of any required regulatory approvals; the ability of Hemisphere to obtain qualified staff, equipment and services in a timely and cost efficient manner; drilling results; the ability of the operator of the projects in which Hemisphere has an interest in to operate the field in a safe, efficient and effective manner; the ability of Hemisphere to obtain financing on acceptable terms; field production rates and decline rates; the ability to replace and expand oil and natural gas reserves through acquisition, development and exploration; the timing and cost of pipeline, storage and facility construction and expansion and the ability of Hemisphere to secure adequate product transportation; future commodity prices; currency, exchange and interest rates; regulatory framework regarding royalties, taxes and environmental matters in the jurisdictions in which Hemisphere operates; and the ability of Hemisphere to successfully market its oil and natural gas products.

The forward‐looking statements included in this news release are not guarantees of future performance and should not be unduly relied upon. Such information and statements, including the assumptions made in respect thereof, involve known and unknown risks, uncertainties and other factors that may cause actual results or events to defer materially from those anticipated in such forward‐looking statements including, without limitation: changes in commodity prices; changes in the demand for or supply of Hemisphere’s products, the early stage of development of some of the evaluated areas and zones; unanticipated operating results or production declines; changes in tax or environmental laws, royalty rates or other regulatory matters; changes in development plans of Hemisphere or by third party operators of Hemisphere’s properties, increased debt levels or debt service requirements; inaccurate estimation of Hemisphere’s oil and gas reserve volumes; limited, unfavourable or a lack of access to capital markets; increased costs; a lack of adequate insurance coverage; the impact of competitors; and certain other risks detailed from time‐to‐time in Hemisphere’s public disclosure documents, (including, without limitation, those risks identified in this news release and in Hemisphere’s Annual Information Form).

The forward‐looking statements contained in this news release speak only as of the date of this news release, and Hemisphere does not assume any obligation to publicly update or revise any of the included forward‐looking statements, whether as a result of new information, future events or otherwise, except as may be required by applicable securities laws.

View full release here.

Release – CoreCivic Announces New Contract Award To Resume Operations At West Tennessee Detention Facility

Posted on by aweinsoff@channelchek.com

Research News and Market Data on CXW

August 14, 2025

PDF Version

BRENTWOOD, Tenn., Aug. 14, 2025 (GLOBE NEWSWIRE) — CoreCivic, Inc. (NYSE: CXW) (“CoreCivic”) announced today that it has been awarded a new contract under an intergovernmental services agreement (IGSA) between the City of Mason, Tennessee, and U.S. Immigration and Customs Enforcement (ICE) to resume operations at the Company’s 600-bed West Tennessee Detention Facility, a facility that has been idle since September 2021.

The IGSA expires in August 2030 and may be further extended through bilateral modification. The agreement provides for a fixed monthly payment plus an incremental per diem payment based on detainee populations. Total annual revenue once the facility is fully activated is expected to be approximately $30 million to $35 million, with margins consistent with the CoreCivic Safety segment. We expect this award to have a minimal impact on earnings in the third quarter of 2025, and accretive to earnings beginning in the fourth quarter of 2025, with full ramp currently expected to be complete by the end of the first quarter of 2026.

Damon T. Hininger, CoreCivic’s Chief Executive Officer, commented, “We are grateful for the trust our government partner has placed in us in reactivating the West Tennessee Detention Facility. Including the West Tennessee Detention Facility, we have reactivated four previously idle facilities aggregating approximately 6,600 beds, and made available to ICE over 1,000 additional detention beds through four contract modifications announced earlier this year, providing the agency with over 7,600 beds to help the agency meet its growing needs.”

Patrick D. Swindle, CoreCivic’s President and Chief Operating Offer added, “We are also grateful for the cooperation the City of Mason has provided in quickly working to expedite the reactivation of the facility. When fully activated, we expect to add well over 200 jobs to the local community, and we look forward to working with the City under this new relationship.”

About CoreCivic

CoreCivic is a diversified, government-solutions company with the scale and experience needed to solve tough government challenges in flexible, cost-effective ways. We provide a broad range of solutions to government partners that serve the public good through high-quality corrections and detention management, a network of residential and non-residential alternatives to incarceration to help address America’s recidivism crisis, and government real estate solutions. We are the nation’s largest owner of partnership correctional, detention and residential reentry facilities, and one of the largest operators of such facilities in the United States. We have been a flexible and dependable partner for government for more than 40 years. Our employees are driven by a deep sense of service, high standards of professionalism and a responsibility to help government better the public good. Learn more at www.corecivic.com.

Cautionary Note Regarding Forward-Looking Statements

This press release includes statements as to our beliefs and expectations of the outcome of future events that are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements may include such words as “anticipate,” “estimate,” “expect,” “project,” “plan,” “intend,” “believe,” “may,” “will,” “should,” “can have,” “likely,” and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. Such forward-looking statements may be affected by risks and uncertainties in CoreCivic’s business and market conditions. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from the statements made. Important factors that could cause actual results to differ are described in the filings made from time to time by CoreCivic with the Securities and Exchange Commission (“SEC”) and include the risk factors described in CoreCivic’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on February 21, 2025. Except as required by applicable law, CoreCivic undertakes no obligation to update forward-looking statements made by it to reflect events or circumstances occurring after the date hereof or the occurrence of unanticipated events.

Contact:  Investors: Jeb Bachmann – Managing Director, Investor Relations – (615) 263-3024
Media: Steve Owen – Vice President, Communications – (615) 263-3107

Release – Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Posted on by aweinsoff@channelchek.com

Research News and Market Data on COCP

August 14, 2025

 Download as PDF

 PDF

Release

 PDF  HTML

10-QFiling

 ZIP  XLS  HTML

XBRL

  • Favorable CDI-988 Phase 1 safety and tolerability reported
  • Challenge study with CDI-988 as a norovirus preventive and treatment planned later this year

BOTHELL, Wash., Aug. 14, 2025 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the three and six months ended June 30, 2025, and provides updates on its antiviral product pipeline, upcoming milestones and business activities.

“Preparations are underway for a Phase 1b norovirus challenge study to evaluate our potent, oral antiviral candidate CDI-988 as a prophylaxis and treatment,” said Sam Lee, Ph.D., Cocrystal’s President and co-CEO. “We are encouraged by the favorable safety and tolerability results from our Phase 1 study with CDI-988. This novel protease inhibitor has the potential to transform how we manage this highly contagious virus, which spreads rapidly in military facilities, cruise ships, nursing homes, hospitals and other confined environments. As a prophylactic treatment, CDI-988 could potentially prevent rapid spread of norovirus outbreaks in close quarters.

“We developed CDI-988 for the treatment of norovirus and coronavirus infections using our proprietary structure-based drug discovery platform technology. We are encouraged by our recent in vitro data demonstrating CDI-988 inhibits newly re-emerging norovirus GII.17 strains that are responsible for the 2024-2025 norovirus outbreaks,” added Dr. Lee.

“The absence of any approved norovirus treatments or vaccines creates a substantial market opportunity for Cocrystal,” said James Martin, Cocrystal’s CFO and co-CEO. “With 685 million global cases annually and a $60 billion worldwide economic impact, norovirus represents one of healthcare’s most pressing unmet needs.”

Antiviral Product Pipeline Overview

We harness our revolutionary, structure-based drug discovery platform technology to engineer next-generation, broad-spectrum antivirals that precisely disrupt viral replication mechanisms. Unlike traditional approaches, our technology identifies compounds that bind to highly conserved regions of viral enzymes, thereby creating a formidable defense against current viral threats as well as their mutations. By specifically targeting these evolutionary-constrained viral regions, our drug candidates maintain efficacy even as viruses mutate, while simultaneously minimizing off-target interactions that typically lead to adverse side effects. This dual advantage represents a significant breakthrough in antiviral drug development. In addition, our innovative methodology fundamentally transforms the conventional drug discovery paradigm by eliminating the inefficient, resource-intensive cycles of high-throughput compound screening and prolonged hit-to-lead optimization. The result is faster identification of promising candidates with superior resistance profiles and safety characteristics.

Influenza Programs
Influenza is a major global health threat that may become more challenging to treat due to the emergence of highly pathogenic avian influenza viruses and resistance to approved influenza antivirals. Currently approved antiviral treatments for influenza are effective but are burdened with significant viral resistance.

Each year there are approximately 1 billion cases of seasonal influenza worldwide, 3-5 million severe illnesses and up to 650,000 deaths. About 8 percent of the U.S. population gets sick from flu each season. In addition to the health risk, influenza is responsible for an estimated $10.4 billion in direct medical costs in the U.S. each year.

  • Oral CC-42344 for the treatment of pandemic and seasonal influenza A
    • Our novel PB2 inhibitor CC-42344 showed excellent in vitro activity against pandemic and seasonal influenza A strains, as well as strains that are resistant to Tamiflu® and Xofluza®.
    • In December 2022 we reported favorable safety and tolerability results from the CC-42344 Phase 1 study.
    • In December 2023 we began a randomized, double-blind, placebo-controlled Phase 2a human challenge study to evaluate the safety, tolerability, viral and clinical measurements of CC-42344 in influenza A-infected subjects in the United Kingdom, following authorization from the UK Medicines and Healthcare Products Regulatory Agency (MHRA).
    • In May 2024 we completed enrollment in the Phase 2a human challenge study.
    • In June 2024 we reported that in vitro studies demonstrated CC-42344 inhibits the activity of the highly pathogenic avian influenza A (H5N1) PB2 protein identified in humans exposed to infected dairy cows.
    • In December 2024 we announced a plan to extend the CC-42344 Phase 2a human challenge study due to unexpectedly low influenza infection among study participants.
    • In May 2025 we reported that CC-42344 was shown to be active against the highly pathogenic 2024 Texas H5N1 avian influenza strain.
  • Inhaled CC-42344 as prophylaxis and treatment for pandemic and seasonal influenza A
    • Our preclinical testing showed superior pulmonary pharmacology with CC-42344, including high exposure to drug and a long half-life.
    • Dry powder inhalation formulation development and toxicology studies have been completed.
  • Influenza A/B program
    • Our efforts to develop a preclinical lead of novel influenza replication inhibitors for pandemic and season influenza are ongoing.

Norovirus Program
Norovirus is a common and highly contagious virus that afflicts people of all ages and causes symptoms of acute gastroenteritis including nausea, vomiting, stomach pain and diarrhea, as well as fatigue, fever and dehydration. There is currently no effective treatment or effective vaccine for norovirus, and the ability to curtail outbreaks is limited.

In the U.S., noroviruses are responsible for an estimated 21 million infections annually, including 109,000 hospitalizations, 465,000 emergency department visits and an estimated 900 deaths. The annual burden of norovirus to the U.S. is estimated at $10.6 billion. Noroviruses are responsible for up to 1.1 million hospitalizations and 218,000 deaths annually in children in the developing world.

  • Oral pan-viral protease inhibitor CDI-988 for the treatment of noroviruses and coronaviruses
    • Our novel, broad-spectrum protease inhibitor CDI-988 is being evaluated as a potential treatment for noroviruses and coronaviruses.
    • CDI-988 has shown in vitro pan-viral activity against multiple norovirus strains.
    • In May 2023 we announced approval of our application to the Australian regulatory agency for a randomized, double-blind, placebo-controlled Phase 1 study to evaluate the safety, tolerability and pharmacokinetics (PK) of CDI-988 in healthy subjects.
    • In August 2023 we announced our selection of CDI-988 as our lead compound for the treatment for noroviruses, in addition to coronaviruses.
    • In July 2024 we reported favorable safety and tolerability results from the single-ascending dose cohorts in the Phase 1 study.
    • In December 2024 we reported favorable safety and tolerability results from the multiple-ascending dose cohorts of the Phase 1 study and the addition of a high-dose cohort.
    • In April 2025 we announced that CDI-988 showed superior broad-spectrum antiviral activity against GII.17 strains, the most prevalent strain in the U.S. and Europe in 2024-2025.
    • In August 2025 we presented favorable safety and tolerability Phase 1 data from all CDI-988 doses, including the high-dose 1200 mg cohort, at the 2025 Military Health System Research Symposium (MHSRS).
    • We plan to initiate a human challenge Phase 1b study in the U.S. in 2025 to evaluate CDI-988 as a norovirus prophylaxis and treatment.

SARS-CoV-2 and Other Coronavirus Program
By targeting viral replication enzymes and proteases, we believe it is possible to develop effective treatments for all diseases caused by coronaviruses including SARS-CoV-2 and its variants, Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). CDI-988 showed potent in vitro pan-viral activity against common human coronaviruses, rhinoviruses and respiratory enteroviruses, as well as against noroviruses. The global COVID-19 therapeutics market is estimated to exceed $16 billion annually by the end of 2031.

  • Oral pan-viral protease inhibitor CDI-988 for the treatment of coronaviruses and noroviruses
    • CDI-988 exhibited superior in vitro potency against SARS-CoV-2 and demonstrated a favorable safety profile and PK properties.
    • In September 2023 we dosed the first healthy subject in our norovirus/coronavirus CDI-988 study, which is expected to serve as a Phase 1 study for both indications.
    • In July 2024 we reported favorable safety and tolerability results from the single-ascending dose cohorts in the Phase 1 study.
    • In December 2024 we reported favorable safety and tolerability results from the multiple-ascending dose cohorts of the Phase 1 study and the addition of a high-dose cohort.
    • In August 2025 we presented favorable safety and tolerability Phase 1 data from all CDI-988 doses, including the high-dose 1200 mg cohort, at the MHSRS.

Second Quarter Financial Results

Research and development (R&D) expenses for the second quarter of 2025 were $1.1 million, compared with $4.3 million for the second quarter of 2024, with the decrease primarily due to the timing of clinical study costs. General and administrative (G&A) expenses for the second quarter of 2025 were $1.0 million, compared with $1.1 million for the second quarter of 2024, with the decrease primarily due to a reduction in salaries and wages.

Net loss for the second quarter of 2025 was $2.1 million, or $0.20 per share, compared with net loss for the second quarter of 2024 of $5.3 million, or $0.53 per share.  

Six Months Financial Results

R&D expenses for the first six months of 2025 were $2.5 million, compared with $7.3 million for the first six months of 2024. G&A expenses for the first half of 2025 were $2.0 million, compared with $2.3 million for the first half of 2024.

Net loss for the first six months of 2025 was $4.4 million, or $0.43 per share, compared with a net loss for the first six months of 2024 of $9.3 million, or $0.91 per share.

Cocrystal reported unrestricted cash as of June 30, 2025 of $4.8 million, compared with $9.9 million as of December 31, 2024. Net cash used in operating activities for the first six months of 2025 was $5.1 million, compared with $8.2 million for the first six months of 2024. The Company had working capital of $4.9 million and 10.2 million common shares outstanding as of June 30, 2025.  

About Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create viable antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our plans for the future development of preclinical and clinical product candidates including the potential of our norovirus product candidate, our plans to initiate a human Phase 1b challenge study for our norovirus product candidate, and our plans with regard to initiating a second human challenge study for CC-42344. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events. Some or all of the events anticipated by these forward-looking statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include, but are not limited to, the risks and uncertainties arising from our need for additional capital to fund our operations over the next 12 months, inflation, the possibility of a recession, interest rate increases, imposed and threated tariffs, and geopolitical conflicts including those in Ukraine and Israel on our Company, our collaboration partners, and on the U.S., UK, Australia and global economies, including manufacturing and research delays arising from raw materials and labor shortages, supply chain disruptions and other business interruptions including any adverse impacts on our ability to obtain raw materials for and otherwise proceed with studies as well as similar problems with our vendors and our current and any future clinical research organization (CROs) and contract manufacturing organizations (CMOs), the progress and results of the studies including any adverse findings or delays, the ability of us and our CROs to recruit volunteers for, and to otherwise proceed with, clinical studies, our and our collaboration partners’ technology and software performing as expected, financial difficulties experienced by certain partners, the results of any current and future preclinical and clinical studies, general risks arising from clinical studies, receipt of regulatory approvals, regulatory changes and any adverse developments which may arise therefrom, potential mutations in a virus we are targeting that may result in variants that are resistant to a product candidate we develop, the potential for the development of effective treatments by competitors which could reduce or eliminate a prospective future market share commercializing any product candidates we may develop in the future, and our ability to meet our future liquidity needs. Further information on our risk factors is contained in our filings with the SEC, including the “Risk Factors” in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Investor Contact:
Alliance Advisors IR
Jody Cain
310-691-7100
jcain@allianceadvisors.com

View full release here.

Release – V2X Appoints Retired Brigadier General Stan Budraitis as Vice President, Business Development – Army Aviation Programs

Posted on by aweinsoff@channelchek.com
V2X (PRNewsfoto/V2X, Inc.)

Research News and Market Data on VVX

August 14, 2025

MCLEAN, Va., Aug. 14, 2025 /PRNewswire/ — V2X (NYSE: VVX), today announced the appointment of Stan Budraitis as Vice President, Business Development – Army Aviation Programs. Budraitis joins V2X following a distinguished 35-year career as a U.S. Army Aviator, retiring in April 2023 as a Brigadier General.

Most recently, Budraitis served as the Deputy Commanding General at the U.S. Army Aviation Center of Excellence and Commandant of the Aviation School at Fort Rucker, Alabama. Throughout his career, he held key leadership and operational roles across Army aviation, including multiple command assignments and two overseas deployments to Afghanistan and Kuwait. He is a Master Army Aviator with over 2,000 flight hours in rotary-wing aircraft, including the UH-1, OH-58, and UH-60.

“Stan’s deep operational experience and strategic insight into Army aviation make him an outstanding addition to the V2X team,” said L. Roger Mason, Chief Growth Officer of V2X. “His leadership will be instrumental in advancing our support for Army aviation customers and expanding our mission-critical capabilities as we pursue new opportunities.”

Budraitis holds a bachelor’s degree in Business Administration from William Carey University and a master’s degree in Strategic Studies from the U.S. Army War College. His military decorations include the Bronze Star Medal (with Oak Leaf Cluster), the Meritorious Service Medal (with four Oak Leaf Clusters), and the Master Army Aviator Badge.

About V2X
V2X builds innovative solutions that integrate physical and digital environments by aligning people, actions, and technology. V2X is embedded in all elements of a critical mission’s lifecycle to enhance readiness, optimize resource management, and boost security. The company provides innovation spanning national security, defense, civilian, and international markets. With a global team of approximately 16,000 professionals, V2X enables mission success by injecting AI and machine learning capabilities to meet today’s toughest challenges across all operational domains.

Investor Contact
Mike Smith, CFA
Vice President, Treasury, Corporate Development and Investor Relations
IR@goV2X.com
719-637-5773

Media Contact
Angelica Spanos Deoudes
Director, Corporate Communications
Angelica.Deoudes@oV2X.com
571-338-5195

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/v2x-appoints-retired-brigadier-general-stan-budraitis-as-vice-president-business-development–army-aviation-programs-302529914.html

SOURCE V2X, Inc.

Release – Unicycive Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

Posted on by aweinsoff@channelchek.com

Research News and Market Data on UNCY

August 14, 2025 7:00am EDT Download as PDF

Related Documents

10-QFiling

 PDF HTML

XBRL

 ZIP XLS HTML

– Type A Meeting requested with U.S. Food and Drug Administration (FDA) for resolution of the Complete Response Letter (CRL) for oxylanthanum carbonate (OLC)

– OLC pivotal study data, published in the Clinical Journal of the American Society of Nephrology (CJASN), demonstrated OLC was well tolerated and enabled serum phosphate control in over 90% of patients with a low pill burden

– Ended Q2 with $22.3 million of cash with expected runway into the second half of 2026

LOS ALTOS, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the three months ended June 30, 2025, and provided a business update.

“Our team has made great progress in the second quarter, and we have requested a Type A meeting with the FDA to resolve the CRL and obtain regulatory approval. We believe we have built multiple approaches to correct the deficiency noted for our third-party manufacturing vendor, which was unrelated to OLC,” said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive. “Meanwhile, the recently published pivotal trial data in CJASN continue to highlight OLC’s best-in-class potential. Given the high rates of patient non-compliance with existing phosphate lowering therapies, we remain fully committed to meeting this clear need for improved treatment options for managing hyperphosphatemia in dialysis patients.”

Key Highlights & Upcoming Milestones

  • Unicycive has requested a Type A meeting with the FDA to discuss resolution of the CRL received in June in regard to its New Drug Application for OLC. Typically, Type A meetings are granted by the FDA within 30 days of the request. The Company plans to provide an investor update in the third quarter once it has received the FDA’s written feedback.
  • In July, the Company announced the publication of pivotal clinical study data describing the safety and tolerability of OLC in CKD patients on dialysis in CJASN. Data demonstrated that OLC was well tolerated, with over 90% of patients achieving effective phosphate control with most individuals needing no more than one tablet per meal.

Financial Results for the Quarter Ended June 30, 2025

Research and Development (R&D) expenses were $1.8 million for the three months ended June 30, 2025, compared to $4.9 million for the three months ended June 30, 2024. The decrease in research and development expenses was primarily due to decreased drug development costs.

General and Administrative (G&A) expenses were $5.2 million for the three months ended June 30, 2025, compared to $2.5 million for the three months ended June 30, 2024. The increase was primarily due to increased consulting and professional services related to our commercial launch preparation.

Other income was $0.5 million for the three months ended June 30, 2025, compared to other income of $17.3 million for the three months ended June 30, 2024, primarily due to the change in fair value of our warrant liability.

Net loss attributable to common stockholders for the three months ended June 30, 2025, was $6.4 million, compared to net income attributable to common stockholders of $3.0 million for the three months ended June 30, 2024. The increased net loss for the three-month period ended June 30, 2025 was primarily due to the change in fair value of our warrant liability.

As of June 30, 2025, cash and cash equivalents totaled $22.3 million. The Company believes that it has sufficient resources to fund operations into the second half of 2026.

About Unicycive Therapeutics

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information about Unicycive, visit Unicycive.com and follow us on LinkedIn and X.

Forward-looking statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend” or other similar terms or expressions that concern Unicycive’s expectations, strategy, plans or intentions. These forward-looking statements are based on Unicycive’s current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; risks related to business interruptions, which could seriously harm our financial condition and increase our costs and expenses; our need to raise substantial additional capital in the future to fund our continuing operations and the development and commercialization of our current product candidates and future product candidates; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; risks related to delays in obtaining or failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; and our failure, or the failure of our third-party manufacturers, or their subcontractors, to comply with cGMPs or other applicable regulations, which could result in sanctions being imposed on us or the manufacturers, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates, operating restrictions and criminal prosecutions, any of which could adversely affect supplies of our product candidates and harm our business and results of operations. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Unicycive’s Annual Report on Form 10-K for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Unicycive specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Investor Contacts:

Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com

Media Contact:

Rachel Visi
Real Chemistry
redery@realchemistry.com

SOURCE: Unicycive Therapeutics, Inc.

View full release here.

Producer Prices Jump Most in 3 Years: Complicates Fed’s Rate Cut Timeline

Posted on by slightbourne@noblecapitalmarkets.com

The Federal Reserve’s carefully orchestrated path toward interest rate cuts hit an unexpected roadblock Thursday as producer price data revealed the most significant inflationary surge in over three years, casting doubt on the central bank’s timeline for monetary easing.

The Producer Price Index (PPI) jumped 0.9% in July, dramatically exceeding economists’ expectations of just 0.2% and marking the sharpest monthly increase since early 2022. This surge pushed annual producer inflation to 3.3%, the highest level since February and a stark reminder that the battle against rising prices remains far from over.

More concerning for policymakers was the performance of core producer prices, which strip out volatile food and energy costs to provide a clearer picture of underlying inflation trends. These prices rose 0.6% monthly, representing the largest increase since March 2022 and a significant acceleration from June’s flat reading. The annual core rate also hit 3.3%, matching February’s peak.

The timing of this inflation shock couldn’t be more problematic for the Federal Reserve. Just days after consumer price data showed inflation pressures remaining stubbornly above the Fed’s 2% target, producer prices have delivered another unwelcome surprise. Markets, which had priced in a virtual certainty of rate cuts beginning in September, are now recalibrating their expectations.

This producer price acceleration tells a troubling story about cost pressures flowing through the economy. Unlike consumer prices, which measure what households pay, producer prices capture the costs businesses face when purchasing goods and services. When these prices rise rapidly, companies face a critical decision: absorb the higher costs and accept reduced profit margins, or pass them along to consumers through higher retail prices.

Recent evidence suggests businesses are increasingly choosing the latter option. Economists point to growing margin pressures from tariffs on imported goods as a key driver behind this trend. Analysis from Nationwide indicates that while companies initially absorbed most tariff-related cost increases, margins are becoming increasingly strained by higher costs for imported goods, leading to expectations of stronger price pass-through to consumers in coming months.

The mechanics behind July’s surge reveal interesting dynamics within the economy. Analysis from Capital Economics highlighted an unusual increase in margins for wholesalers and retailers, suggesting that some of the price increases reflect strategic business decisions rather than pure cost pressures. This margin expansion indicates companies may be regaining pricing power after years of competitive pressure.

Financial markets reacted swiftly to the news, with stock indices declining as investors grappled with the implications for Federal Reserve policy. The probability of a September rate cut, which stood at 100% just Wednesday, dropped to approximately 95% following the release, while expectations for a larger 0.5% cut nearly evaporated entirely.

The producer price shock arrives at a particularly sensitive moment for Federal Reserve Chair Jerome Powell, who is scheduled to address the Jackson Hole Economic Symposium on August 22. This highly anticipated speech was expected to lay the groundwork for the Fed’s transition from restrictive monetary policy to a more accommodative stance. However, the recent inflation data complicates that narrative considerably.

For consumers already feeling the squeeze from elevated prices, the producer price surge offers little comfort. With businesses facing higher input costs and showing increased willingness to pass these expenses along, household budgets may face additional pressure in the months ahead. The disconnect between the Fed’s 2% inflation target and current price trends suggests that relief for American families remains elusive.

The path forward for monetary policy now appears more uncertain than at any point in recent months. While labor market softening and economic growth concerns continue to build the case for rate cuts, persistent inflation pressures argue for maintaining restrictive policies longer. Powell and his colleagues face the challenging task of balancing these competing forces while maintaining credibility in their inflation-fighting mission.

As markets await Powell’s Jackson Hole remarks, one thing has become clear: the Federal Reserve’s policy decisions will require careful calibration as conflicting economic signals continue to complicate the monetary policy landscape.

The Oncology Institute, Inc. (TOI) – Patient Additions And Pharmacy Division Drive 2Q25 Revenues Above Expectations

Posted on by slightbourne@noblecapitalmarkets.com


Thursday, August 14, 2025

TOI is an oncology practice management company that provides administrative services to oncology clinics. These clinics provide cancer care to a population of approximately 1.9 million patients. Services include cancer care, pharmacy and dispensary services, clinical trials, and services associated with oncology care. The company employs nearly 120 clinicians and over 700 teammates at over 70 clinic locations.

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Revenues Were Driven By New Patients Under Contract. The Oncology Institute reported a loss for 2Q25 of $17.0 million or $(0.15) per share. Revenues of $119.8 million exceeded our estimate of $110.4 million. The company discussed newly active or pending contracts that will add covered lives during 2H25. It reiterated its guidance for Revenues, Gross Profit, Adjusted EBITDA, and Free Cash Flow. Cash on June 30, 2025 was $30.3 million.

Patient Services Were Close To Our Expectations. The Patient Services division reached $55.9 million. New payor contracts added patients during 1H25 that began generating revenues, although they have a period of higher cost during the transition to TOI management. We expect the patient mix to include more continuing patients during 2H25, improving margins while new contracts continue to drive growth.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

SKYX Platforms (SKYX) – Revised Forecasts Reflect Phased Rollout, Long-Term Outlook Intact

Posted on by slightbourne@noblecapitalmarkets.com


Thursday, August 14, 2025

Patrick McCann, CFA, Research Analyst, Noble Capital Markets, Inc.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Q2 results. SKYX reported Q2 revenue of $23.1 million, up 7.5% year over year and 14.7% sequentially. Gross margin expanded 190bps to 30.3%, supported by a favorable mix shift toward proprietary tech-embedded products. The adj. EBITDA loss of $2.6 million was slightly wider than our forecast of a $2.3 million loss but reflects underlying operating leverage as revenue scales.

Smart City partnership reinforces revenue growth trajectory. The company’s partnership with the $3 billion Smart City development in Miami’s Little River District positions it for sustained long-term growth. We expect the rollout to drive meaningful topline and branding impact over time, with strategic visibility among large-scale developers likely to reinforce future adoption of SKYX’s technology in both residential and commercial verticals.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Bitcoin Tumbles on Hot Inflation Data

Posted on by slightbourne@noblecapitalmarkets.com

Bitcoin’s remarkable ascent to record highs came to an abrupt halt Thursday as inflation concerns and policy clarity sent the cryptocurrency tumbling more than 3% from its peak above $123,500.

The selloff began after July’s producer price data showed a shocking 0.9% monthly increase versus expectations of just 0.2%, immediately cooling market expectations for aggressive Federal Reserve rate cuts. The inflation surprise highlighted bitcoin’s sensitivity to monetary policy shifts and broader economic conditions.

Adding pressure were comments from Treasury Secretary Scott Bessent clarifying the government’s approach to bitcoin reserves. While acknowledging the US holds $15-20 billion worth of bitcoin, Bessent stated the government won’t actively purchase cryptocurrency for strategic reserves, instead relying on asset seizures and confiscations for any growth.

This dual blow highlighted bitcoin’s vulnerability to both policy uncertainty and macroeconomic headwinds, demonstrating how quickly bullish narratives can shift.

The broader cryptocurrency market suffered alongside bitcoin, with Ethereum falling 3.6% and MicroStrategy dropping over 4%. The selloff underscored how crypto assets remain closely tied to traditional financial market dynamics despite their decentralized nature.

Bitcoin’s recent surge had been fueled by corporate treasury adoption, following MicroStrategy’s strategy of adding bitcoin to balance sheets. Spot bitcoin ETF inflows and the Trump administration’s pro-crypto stance, including executive orders exploring cryptocurrency in 401(k) plans, had provided additional momentum.

However, Thursday’s action reminded investors that bitcoin’s correlation with traditional risk assets strengthens during uncertainty periods. As investors reassessed Fed policy prospects amid persistent inflation, they simultaneously reduced appetite for speculative investments.

The inflation data’s impact highlights bitcoin’s evolution from purely speculative asset to one increasingly influenced by mainstream financial conditions. Higher producer prices suggest inflationary pressures may persist, potentially keeping monetary policy restrictive longer than anticipated.

For bitcoin investors, the environment presents competing forces. While long-term structural support remains through corporate adoption and regulatory clarity, near-term price action appears tied to economic conditions and policy developments. Bitcoin’s ability to maintain recent gains may depend on inflation trends and Fed policy decisions.

Despite Thursday’s pullback, fundamental drivers supporting bitcoin’s longer-term outlook remain intact. Corporate demand continues, regulatory frameworks are clarifying, and institutional infrastructure keeps expanding. However, the day’s events showed that even bullish crypto narratives remain subject to monetary policy and economic realities.

Trading around $118,400 after the decline, bitcoin’s next move likely depends on whether inflation pressures build or moderate, directly influencing both monetary policy expectations and risk asset appetite. The intersection of traditional monetary policy and cryptocurrency markets has never been clearer, suggesting bitcoin’s path forward will remain closely tied to broader economic conditions.

Gildan and HanesBrands Join Forces to Create a Global Powerhouse in Basic Apparel

Posted on by slightbourne@noblecapitalmarkets.com

In a landmark deal set to reshape the global apparel industry, Gildan Activewear Inc. and HanesBrands Inc. have agreed to merge, forming one of the largest basic apparel companies in the world. The agreement, announced August 13, 2025, combines two industry leaders with complementary strengths, aiming to expand market reach, enhance manufacturing efficiency, and unlock significant cost savings.

The transaction values HanesBrands at approximately $2.2 billion in equity and $4.4 billion in enterprise value. Upon completion, HanesBrands shareholders will own about 19.9% of the combined company. The deal is expected to close in late 2025 or early 2026, pending shareholder and regulatory approvals.

The merger will give Gildan access to HanesBrands’ iconic innerwear labels such as Hanes, Playtex, and Maidenform, while strengthening its retail penetration for its own activewear brands. The companies plan to leverage their combined strengths to expand sales across multiple channels and geographies.

Gildan’s vertically integrated, low-cost manufacturing network is a core advantage in the deal. By combining operations, the new entity expects to realize at least $200 million in annual cost synergies within three years—$50 million in 2026, $100 million in 2027, and another $50 million in 2028. These savings will come from streamlining supply chains, consolidating production, and reducing overlapping expenses.

From day one, the transaction is expected to boost Gildan’s adjusted diluted earnings per share, with projected growth of over 20% once full synergies are achieved. The combined entity’s adjusted EBITDA would have been approximately $1.6 billion for the 12 months ending June 29, 2025.

With greater scale, a broader product range, and enhanced brand strength, the merged company is positioned to better withstand seasonal and economic fluctuations. By blending HanesBrands’ strong retail presence with Gildan’s manufacturing efficiency, the partnership aims to offer greater value to both customers and shareholders.

The combined company will remain headquartered in Montréal, Québec, while maintaining a strong presence in Winston-Salem, North Carolina, preserving HanesBrands’ historical roots. Additionally, Gildan plans to review strategic alternatives for HanesBrands Australia, which could include a sale or other restructuring.

Looking ahead, Gildan projects net sales growth of 3–5% annually from 2026 to 2028, with capital expenditures of 3–4% of sales to support growth and integration. The company intends to resume share buybacks once its leverage ratio returns to target levels.

If successful, the merger will create a dominant player in the basic apparel space, offering a more diversified product portfolio, expanded global reach, and a more resilient supply chain. For both brands, this union marks a significant step toward shaping the future of affordable, high-quality apparel worldwide.

Release – Alliance Resource Partners, L.P. Announces the Promotion of Jesse M. Parrish to Sr. Vice President and Chief Commercial Officer of Alliance Coal, LLC

Posted on by aweinsoff@channelchek.com

Research News and Market Data on ARLP

August 13, 2025

TULSA, Okla.–(BUSINESS WIRE)– Alliance Resource Partners, L.P. (NASDAQ: ARLP) is pleased to announce the promotion of Jesse M. Parrish to Sr. Vice President and Chief Commercial Officer of ARLP’s subsidiary, Alliance Coal, LLC (“Alliance Coal”), effective immediately. In Mr. Parrish’s expanded role, he will oversee Alliance Coal’s commercial strategy including oversight of the sales, marketing, and logistics functions as well as its government relation functions. Mr. Parrish will continue to report to Joseph W. Craft III, President and Chief Executive Officer of Alliance Coal and ARLP.

Mr. Craft explained, “Jesse’s expanded role is a natural evolution of our vision for him as he assumes more of my day-to-day responsibilities allowing me more time to focus on strategic growth opportunities for ARLP. President Trump has declared his administration will do whatever it takes to ensure that the United States can build and maintain the largest, most powerful and most advanced AI infrastructure anywhere on the planet. To achieve global AI dominance, America has to maintain, extend and expand the current electric generating assets and invest significantly in new generation infrastructure. ARLP’s aim is to pursue opportunities in the growing power infrastructure sector and preserve our nation’s coal fleet.”

Mr. Parrish joined Alliance Coal in April 2025 as Senior Vice President of Operations and previously spent over a decade in different senior capacities in the eastern U.S. coal industry. Timothy J. Whelan’s role as Sr. Vice President of Sales and Marketing, will remain unchanged, and he and his team remain the primary contact for Alliance Coal’s customers and other commercial partners.

About Alliance Resource Partners, L.P.

ARLP is a diversified energy company that is currently the second largest coal producer in the eastern United States, supplying reliable, affordable energy domestically and internationally to major utilities, metallurgical and industrial users. ARLP also generates operating and royalty income from mineral interests it owns in strategic coal and oil & gas producing regions in the United States. In addition, ARLP is positioning itself as a reliable energy partner for the future by pursuing opportunities that support the growth and development of energy and related infrastructure.

News, unit prices and additional information about ARLP, including filings with the Securities and Exchange Commission (“SEC”), are available at www.arlp.com. For more information, contact the investor relations department of ARLP at (918) 295-7673 or via e-mail at investorrelations@arlp.com.

Investor Relations Contact
Cary P. Marshall
Senior Vice President and Chief Financial Officer
(918) 295-7673
investorrelations@arlp.com

Source: Alliance Resource Partners, L.P.